Tim Mitchell, chief executive of Sareum Holdings Plc (LON:SAR) tells Proactive the company's posted a maiden profit after receiving the first payments from licensing lead product, a Chk1 inhibitor cancer candidate, to Sierra Oncology.
Cancer drug payment nudges Sareum Holdings into maiden profit
Quick facts: Sareum Holdings PLC
Price: 0.4 GBX
Market Cap: £12.29 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE